Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.
Matambo R, Nyandoro G, Sandy C, Nkomo T, Mutero-Munyati S, Mharakurwa S, Chikaka E, Ngwenya M, Ndongwe G, Pepukai VM. Matambo R, et al. Pan Afr Med J. 2021 Jun 15;39:128. doi: 10.11604/pamj.2021.39.128.27726. eCollection 2021. Pan Afr Med J. 2021. PMID: 34527144 Free PMC article.
Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
Matambo R, Takarinda KC, Thekkur P, Sandy C, Mharakurwa S, Makoni T, Ncube R, Charambira K, Zishiri C, Ngwenya M, Nyathi S, Chiteka A, Chikaka E, Mutero-Munyati S. Matambo R, et al. PLoS One. 2020 Apr 30;15(4):e0230848. doi: 10.1371/journal.pone.0230848. eCollection 2020. PLoS One. 2020. PMID: 32353043 Free PMC article.
The role of bacteriological monitoring using culture and drug susceptibility tests (CDST) on treatment outcomes among MDR/RR-TB patients on treatment: a cohort analysis of patients enrolled on treatment 2010-2015 in Zimbabwe.
Matambo R, Mutero-Munyati S, Pepuka VM, Nkomo T, Sandy C, Ngwenya M, Ndongwe G, Chikaka E, Mharakurwa S, Nyandoro G. Matambo R, et al. Pan Afr Med J. 2021 Jun 2;39:97. doi: 10.11604/pamj.2021.39.97.26796. eCollection 2021. Pan Afr Med J. 2021. PMID: 34466199 Free PMC article.
TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
Chipinduro M, Timire C, Chirenda J, Matambo R, Munemo E, Makamure B, Nhidza AF, Tinago W, Chikwasha V, Ngwenya M, Mutsvangwa J, Metcalfe JZ, Sandy C. Chipinduro M, et al. Among authors: matambo r. Int J Tuberc Lung Dis. 2022 Jan 1;26(1):57-64. doi: 10.5588/ijtld.21.0341. Int J Tuberc Lung Dis. 2022. PMID: 34969430 Free PMC article.
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. Jindani A, et al. N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210. N Engl J Med. 2014. PMID: 25337749 Free PMC article. Clinical Trial.
13 results